Investigation on the individualized starting dose of 6-mercaptopurine based on pharmacogenetics
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0006822
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. 1 year < age < 21 years old
2. Newly diagnosed pediatric acute lymphoblastic leukemia patients who achieved complete remission through remission induction therapy
3. Patients who have pharmacogenetics results and start maintenance therapy
Exclusion Criteria
1. Patients who plan to undergo hematopoietic stem cell transplantation
2. Patients who have relapsed
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total duration of treatment discontinuation during maintenance therapy
- Secondary Outcome Measures
Name Time Method Frequency of neutropenia (ANC <500) during maintenance therapy/Percentage of neutropenic fever during maintenance therapy/Relapsed rate